CB-101 · Aurelia
Aurelia™
Pediatric neuro-oncology — a tolerability-led reformulation for fragile young physiologies.
Discovery
Preclinical
Phase I
Phase II
FDA Submission
Home — Research & Services
Five candidates presently occupy our benches — four maturing through advanced development, one poised at the threshold of FDA submission. Alongside them, our white-label faculty serves partners who require manufacture and packaging of impeccable provenance.
Each programme is plotted across our five-gate development continuum. Hover to dwell; scroll to watch each gate resolve.
Pediatric neuro-oncology — a tolerability-led reformulation for fragile young physiologies.
Supportive therapy for pediatric leukaemia — engineered to soften the burden of treatment.
Targeted delivery architecture for pediatric solid tumours — routing therapy with discernment.
A palatable anti-emetic reformulation calibrated for the youngest oncology patients.
An oncology-supportive formulation — our most mature candidate, dossier prepared for regulatory filing.
Of five active candidates, four advance through Phase II and one stands prepared for FDA submission — evidence of a pipeline maturing in concert rather than isolation.
active candidates in portfolio
advancing through Phase II
ready for FDA submission
pediatric-oncology aligned
Candidates by stage
For partners who require generic medicines produced with provenance, we extend our cGMP faculty as a service — manufacturing and packaging to order, governed by a minimum order quantity and the same scrutiny we reserve for our own candidates.
From formulation transfer to finished, market-ready packaging — a single accountable counterpart across the whole chain.
Request a Capabilities Brief →